Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 1997

View Archived Issues

Sankyo prepares antifungal agents

Gelatinase inhibitors prepared by Ono

Roussel Uclaf reports agents for BPH

Prostaglandin derivatives from Ono

MMP inhibitors described by Kureha

Merck KGaA's new ET antagonists

Na+/K+-exchange inhibitors from Merck KGaA

Novel LT biosynthesis inhibitor discovered by Abbott

Recombinant human hemoglobin produced by transgenic tobacco

Annual Report: Celltech

Annual Report: Ergo Science

Biogen and CV Therapeutics codevelop cardiovascular therapy

Novo Nordisk characterizes potential antipsychotic agent

Aradigm awarded NIH SBIR grant for respiratory disease therapy

AEterna enters into agreement to finance clinical studies with Neovastat

Successful animal study of PDIT for metastatic breast cancer

P-glycoprotein prevents absorption of saquinavir

Eurand develops taste-masked form of ketoprofen

PDT with Photofrin for early-stage esophageal and lung cancer

Painless local dermal anesthesia now available

Clinical testing of Visualine II tests completed

Cytogen seeks Canadian approval for Quadramet

Lark studies link between cell immortalization and tumor malignancy

Cel-Sci purchases complete rights to Multikine

Atorvastatin approved in Canada

LifeCell reports first sales of Alloderm products

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...